Regulatory T Cells in Organ Transplantation

Lactate trends reveal organ transplant viability

This episode explores the critical role of **lactate metabolism** as a biomarker for assessing organ quality in **Donation after Circulatory Death (DCD)** compared to **Donation after Brain Death (DBD)**. While the heart typically consumes lactate and the liver clears it, the **warm ischemia** inherent in DCD causes a shift toward anaerobic metabolism and significant lactate accumulation. To mitigate this injury, advanced **ex vivo perfusion** and **normothermic regional perfusion** techniques are utilized to monitor **lactate clearance trends** as a primary indicator of graft viability. While absolute thresholds exist, such as specific millimole targets for livers and hearts, the **downward trajectory** of lactate levels during perfusion is a more reliable predictor of post-transplant success. Clinical data suggest that when these metabolic markers are managed effectively, DCD organs can achieve **survival outcomes** comparable to traditional DBD grafts. Ultimately, the conversation highlights how **metabolic monitoring** transforms high-risk donor organs into viable options for transplantation.

The Future of Transplant (Organ Transplantation in 2050)

By 2050, organ transplantation will be radically transformed—from a scarce, donor-dependent therapy into a diverse ecosystem of biological and technological solutions. Patients will receive organs from genetically engineered pigs, bioprinting labs, or even their own regenerated cells, while many others may avoid transplantation altogether through regenerative medicine, gene editing, and artificial organ implants. Advances in AI-driven allocation, precision medicine, and opt-out donation policies will expand access and efficiency, though disparities may persist between rich and poor regions. As bioengineered and artificial organs blur the boundaries between human, animal, and machine, the ethical, psychological, and cultural dimensions of identity, equity, and mortality will become central. Ultimately, the future of end-stage organ disease lies not only in replacing organs but in redefining what it means to heal, live, and thrive beyond biological limits.

Regulatory T Cells in Organ Transplantation

Regulatory T cells (Tregs)—discovered by Shimon Sakaguchi, Mary Brunkow, and Fred Ramsdell, who were awarded the 2025 Nobel Prize—are central to inducing immune tolerance and preventing organ transplant rejection. These CD4⁺FoxP3⁺ cells suppress alloimmune responses through multiple mechanisms (IL-10, TGF-β secretion; CTLA-4–mediated dendritic cell modulation; IL-2 consumption; cytotoxic effects on effector T cells). Clinically, higher Treg levels correlate with better graft survival and fewer rejection episodes. Early-phase trials in kidney and liver transplantation show that adoptive Treg infusions are safe, reduce acute rejection, and allow lowering of toxic immunosuppressive drugs. Approaches include polyclonal Tregs, donor-specific Tregs (darTregs), low-dose IL-2 to expand Tregs in vivo, and cutting-edge CAR-engineered Tregs for precise graft targeting. Key challenges remain—maintaining Treg stability and specificity, avoiding off-target immunosuppression, and overcoming complex cell manufacturing. Future directions focus on CAR/FOXP3-engineered “super Tregs,” orthogonal IL-2 systems for selective in vivo expansion, biomaterial-based delivery, and scalable Treg production from thymus or iPSCs. These advances aim to achieve durable, donor-specific tolerance with minimal lifelong immunosuppression—potentially transforming transplant care.

Desensitization and Pheresis in Kidney Transplant

Desensitization has transformed kidney transplantation for patients with high immunologic risk by lowering or removing antibodies that would otherwise cause graft loss. Pre- and peri-transplant plasmapheresis (therapeutic plasma exchange) with low-dose intravenous immunoglobulin (IVIG), sometimes combined with B-cell depletion (rituximab) or newer agents (imlifidase, bortezomib, daratumumab), is standard for HLA- or ABO-incompatible living and deceased donor transplants. Plasmapheresis is also first-line therapy for antibody-mediated rejection and for recurrent focal segmental glomerulosclerosis (FSGS), where early, intensive sessions can induce remission; resistant cases may benefit from lipoprotein apheresis. Highly sensitized patients are identified by elevated panel reactive antibody (PRA/cPRA) levels; allocation systems now prioritize these candidates, but desensitization remains key when compatible organs are unavailable. Pediatric protocols aim to minimize apheresis burden while maintaining good graft survival. In parallel, xenotransplantation—especially gene-edited pig kidneys—is entering early human trials; here, preemptive or rescue plasmapheresis/IVIG has shown utility in controlling anti-pig antibody responses. Emerging strategies target long-lived plasma cells, complement pathways, and precise antibody monitoring to make incompatible and xenogeneic transplantation safer and more durable.

Organ Offer Review - Kidney and Liver Transplant

When a deceased-donor offer arrives, the on-call surgeon rapidly weighs donor organ quality, recipient need, and logistics within OPTN/UNOS policy. For kidneys, decisions hinge on KDPI, creatinine/AKI course, machine-pump metrics, procurement biopsy (e.g., glomerulosclerosis/arteriosclerosis), HLA antibodies/virtual or physical crossmatch, and the patient’s wait time/sensitization; kidneys tolerate longer cold ischemia and can be deferred a few hours if needed. For livers, the focus is MELD/urgency, donor stability (pressors/arrest), DCD status and warm ischemia, steatosis by appearance/biopsy, extreme transaminases, size match, and the ability to transplant quickly (short cold time ± normothermic perfusion), with far less emphasis on HLA. Logistics—distance/transport mode, OR and team readiness, projected cold ischemia, and availability of perfusion—can tip the balance for either organ. Donor infections (e.g., HCV NAT+) are acceptable with informed consent and modern antivirals; ABO compatibility is mandatory (liver ABO-incompatible only in rare emergencies). UNOS DonorNet, offer filters, image/biopsy sharing, and emerging AI triage tools streamline evaluation, while center-specific protocols and national metrics encourage timely, appropriate acceptance rather than reflexive decline. Ethically, surgeons balance utility and equity—accepting enough risk to save the right patient now without wasting scarce grafts—recognizing that kidney transplantation is comparatively elective in timing, whereas liver transplantation is often urgent and less forgiving of delay.